Unique Pharmaceuticals, a 503B outsourcing facility, has initiated sterile compounding operations meeting the newly established federal guidelines. “Our goal as a company is to meet and exceed industry standards,” said Unique Pharmaceuticals chief executive officer Travis Leeah. “Meeting the new regulations is validation of our quality management system and our dedicated staff. We’re embracing the future of our industry, investing in its continued success and are proud...